However, whether anti-PD-1/PD-L1 treatment would be beneficial for COVID-19 patients has to be investigated, since this treatment might enhance the cytokine storm associated with higher COVID-19 morbidity and mortality [59, 60]. This evidence concerns the gene PDCD1 and COVID-19.